Coramaze Technologies has developed the TriPair Tricuspid Repair System, a minimally invasive device that utilizes a flexible inflatable spacer to address tricuspid regurgitation, a condition that can lead to heart failure and significantly reduces survival rates. The system streamlines the repair procedure to under 20 minutes without the need for anesthesia or transesophageal echocardiography, providing an effective solution for patients lacking alternative therapies.
Funding
$5.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Tricuspid regurgitation (TR), a condition where the tricuspid valve doesn't close properly, leads to blood flowing back into the heart. Moderate to severe TR can result in heart failure, end-organ damage, frequent hospitalizations, and reduced survival rates, with limited effective treatment options available for many patients.
Solution
Coramaze Technologies offers the TriPair Tricuspid Repair System, a minimally invasive solution designed to address tricuspid regurgitation. The system utilizes a flexible, inflatable spacer that fills the gaps in the leaflets of the tricuspid valve, restoring proper function. The TriPair system is designed for straightforward deployment using standard catheterization techniques under fluoroscopic guidance. The procedure is designed to be completed quickly, without the need for general anesthesia or transesophageal echocardiography (TEE), making it accessible to a broader range of patients.
Target Audience
The primary target audience includes interventional cardiologists and structural heart specialists treating patients with tricuspid regurgitation who are seeking a minimally invasive and effective repair option.
Features
- Flexible inflatable spacer conforms to valve morphology for effective gap filling.
- Minimally invasive delivery via standard catheterization techniques.
- Fluoroscopy-based deployment for ease of use and a fast learning curve.
- Short procedure time (under 20 minutes) to improve cath lab efficiency.
- No general anesthesia or TEE required, expanding patient eligibility.
- Repeatable thoracic echo-based efficacy testing for optimal outcomes.